INVO INVO BIOSCIENCE INC

INVO Fertility to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025

INVO Fertility to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025

SARASOTA, Fla., May 27, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the “Company”), a healthcare services fertility company focused on expanding access to advanced treatment through the establishment, acquisition and operation of fertility clinics and related businesses and technologies, will participate in a webcast fireside chat and host one-on-one meetings with investors at the Lytham Partners Spring 2025 Investor Conference, taking place virtually on Thursday, May 29, 2025.

Company Webcast

The webcast presentation will take place at 4:15 p.m. ET on Thursday, May 29, 2025. The webcast can be accessed by visiting the conference home page at or directly at . The webcast will also be available for replay following the event.

1x1 Meetings

Management will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at or register for the event at .

About INVO Fertility

We are a healthcare services fertility company dedicated to expanding assisted reproductive technology (”ART”) care to patients in need. Our principal commercial strategy is focused on building, acquiring and operating fertility clinics, including “INVO Centers” dedicated primarily to offering the intravaginal culture (“IVC”) procedure enabled by our INVOcell® medical device (“INVOcell”) and US-based, profitable in vitro fertilization (“IVF”) clinics. We have two operational INVO Centers in the United States and one IVF clinic. We also continue to engage in the sale and distribution of our INVOcell technology solution into third-party owned and operated fertility clinics. The INVOcell is a proprietary and revolutionary medical device, and the first to allow fertilization and early embryo development to take place in vivo within the woman's body. The IVC procedure provides patients with a more natural, intimate, and affordable experience in comparison to other ART treatments. We believe the IVC procedure can deliver comparable results at a fraction of the cost of traditional IVF and is a significantly more effective treatment than intrauterine insemination (“IUI”). For more information, please visit .

For more information, please contact:

INVO Fertility, Inc.

Steve Shum, CEO

978-878-9505

Investor Contact

Lytham Partners, LLC

Robert Blum

602-889-9700



EN
27/05/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on INVO BIOSCIENCE INC

 PRESS RELEASE

INVO Fertility Announces a 1:3 Reverse Stock Split Effective Pre-Marke...

INVO Fertility Announces a 1:3 Reverse Stock Split Effective Pre-Market Opening on July 21, 2025 SARASOTA, Fla., July 17, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (“INVO”) (NASDAQ: IVF), a healthcare company focused on the fertility market, announced today that it will effect a 1-for-3 reverse split of its issued and outstanding and authorized common stock effective as of 12:01 a.m. Eastern Time on July 21, 2025. Commencing with the opening of trading on The Nasdaq Capital Market on July 21, 2025, the Company’s common stock will trade on a post-split basis under the same trading symb...

 PRESS RELEASE

INVO Fertility Enhances INVOcell Technology with Expanded Awareness, T...

INVO Fertility Enhances INVOcell Technology with Expanded Awareness, Training, and Improved Pricing SARASOTA, Fla., July 09, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the “Company”), a healthcare company focused on the fertility market, today announced further efforts to drive its comprehensive strategy to enhance fertility services through expanded clinical and embryology training support and improved pricing for its innovative INVOcell® technology. This underscores the Company’s dual mission as an innovator of cutting-edge fertility solutions and a...

 PRESS RELEASE

INVO Fertility Adds Platelet-Rich Plasma Therapy Capabilities at Wisco...

INVO Fertility Adds Platelet-Rich Plasma Therapy Capabilities at Wisconsin Fertility Institute MIDDLETON, Wis. and SARASOTA, Fla., June 30, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the “Company”), a healthcare company focused on the fertility market, is excited to announce the addition of Platelet-Rich Plasma (PRP) therapy to its comprehensive suite of fertility services at its Wisconsin Fertility Institute center. This cutting-edge treatment offers additional options for individuals and couples facing fertility challenges, further expanding the cen...

 PRESS RELEASE

INVO Fertility Receives Notice of Allowance for Modified INVOcell Devi...

INVO Fertility Receives Notice of Allowance for Modified INVOcell Device Patent SARASOTA, Fla., June 25, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the “Company”), a healthcare company focused on the fertility sector, today announced it has received a notice of allowance on a new patent for a modified version of the Company’s proprietary INVOcell device. The new patent extends intellectual property protection on the Company’s INVOcell device through 2040 based on a modified design which reflects feedback from leading embryologists to simplify use of t...

 PRESS RELEASE

INVO Fertility Reminds Shareholders to Cast Their Vote for Upcoming An...

INVO Fertility Reminds Shareholders to Cast Their Vote for Upcoming Annual Meeting of Shareholders to be held on Wednesday, June 25, 2025 at 12:00 p.m. Eastern Time SARASOTA, Fla., June 20, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the “Company”), a healthcare fertility focused company, reminds shareholders to vote their shares online ahead of the upcoming annual meeting of shareholders (the "Annual Meeting") to be held on June 25, 2025 at 12:00 p.m. Eastern Time. The Board of Directors (the "Board") unanimously recommends that the Company's sharehol...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch